Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Trial ID or NCT#
Status
Purpose
This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.
Official Title
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures
Eligibility Criteria
- * Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven* Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2* Hemoglobin ≥ 9 gm/dL* White blood cell count \> 3000/mm\^3* Platelet count ≥ 100,000/mm\^3* Serum creatinine ≤ 1.5 times upper reference range
- * Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment* History of infusion reactions to monoclonal antibody therapies* Pregnant or breastfeeding* Magnesium or potassium lower than the normal institutional values* Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis* Prisoners, institutionalized individuals, and patients unable to consent for themselves
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jake Jungmin Kim
jakejkim@stanford.edu
View on ClinicalTrials.gov